65 related articles for article (PubMed ID: 17878488)
1. Erlotinib in pancreatic cancer patients: do we need more information from the NCIC CTG trial?
Mandalà M; Moro C; Labianca R; Ferretti G
J Clin Oncol; 2007 Sep; 25(27):4320-1; author reply 4321-2. PubMed ID: 17878488
[No Abstract] [Full Text] [Related]
2. Erlotinib: success of a molecularly targeted agent for the treatment of advanced pancreatic cancer.
Welch SA; Moore MJ
Future Oncol; 2007 Jun; 3(3):247-54. PubMed ID: 17547518
[TBL] [Abstract][Full Text] [Related]
3. First-line erlotinib inferior to chemo in advanced lung cancer.
Oncology (Williston Park); 2012 Oct; 26(10):930-1. PubMed ID: 23176004
[No Abstract] [Full Text] [Related]
4. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.
Lilenbaum R; Axelrod R; Thomas S; Dowlati A; Seigel L; Albert D; Witt K; Botkin D
J Clin Oncol; 2008 Feb; 26(6):863-9. PubMed ID: 18281658
[TBL] [Abstract][Full Text] [Related]
5. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
Herbst RS; Prager D; Hermann R; Fehrenbacher L; Johnson BE; Sandler A; Kris MG; Tran HT; Klein P; Li X; Ramies D; Johnson DH; Miller VA;
J Clin Oncol; 2005 Sep; 23(25):5892-9. PubMed ID: 16043829
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.
Scagliotti GV; Novello S; Schiller JH; Hirsh V; Sequist LV; Soria JC; von Pawel J; Schwartz B; Von Roemeling R; Sandler AB
Clin Lung Cancer; 2012 Sep; 13(5):391-5. PubMed ID: 22440336
[TBL] [Abstract][Full Text] [Related]
7. Erlotinib: recent clinical results and ongoing studies in non small cell lung cancer.
Perez-Soler R
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4589-92. PubMed ID: 17671146
[TBL] [Abstract][Full Text] [Related]
8. A review of kinases implicated in pancreatic cancer.
Giroux V; Dagorn JC; Iovanna JL
Pancreatology; 2009; 9(6):738-54. PubMed ID: 20090395
[TBL] [Abstract][Full Text] [Related]
9. Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways.
Sandler A; Herbst R
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4421s-4425s. PubMed ID: 16857821
[TBL] [Abstract][Full Text] [Related]
10. Angiogenesis inhibition in the treatment of lung cancer.
Vokes E; Herbst R; Sandler A
Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
[TBL] [Abstract][Full Text] [Related]
11. Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer?
Laurent-Puig P; Taieb J
Curr Opin Oncol; 2008 Jul; 20(4):454-8. PubMed ID: 18525343
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response.
Tzeng CW; Frolov A; Frolova N; Jhala NC; Howard JH; Vickers SM; Buchsbaum DJ; Heslin MJ; Arnoletti JP
Ann Surg Oncol; 2007 Jul; 14(7):2150-8. PubMed ID: 17453292
[TBL] [Abstract][Full Text] [Related]
13. Does erlotinib restore chemosensitivity to chemotherapy in pancreatic cancer? A case series.
Saif MW
Anticancer Res; 2011 Mar; 31(3):1039-42. PubMed ID: 21498735
[TBL] [Abstract][Full Text] [Related]
14. Erlotinib in previously treated non-small-cell lung cancer.
Shepherd FA; Rodrigues Pereira J; Ciuleanu T; Tan EH; Hirsh V; Thongprasert S; Campos D; Maoleekoonpiroj S; Smylie M; Martins R; van Kooten M; Dediu M; Findlay B; Tu D; Johnston D; Bezjak A; Clark G; Santabárbara P; Seymour L;
N Engl J Med; 2005 Jul; 353(2):123-32. PubMed ID: 16014882
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials.
Tuma RS
J Natl Cancer Inst; 2007 Mar; 99(5):348-9. PubMed ID: 17341725
[No Abstract] [Full Text] [Related]
16. Combining epidermal growth factor receptor inhibitors and radiation therapy in pancreatic cancer: small step or giant leap?
Chang BW; Saif MW
JOP; 2009 May; 10(3):231-6. PubMed ID: 19454812
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of erlotinib plus capecitabine as first-line treatment for metastatic pancreatic cancer (XELTA study).
López R; Méndez CM; Fernández MJ; Reinoso CR; Aldana GQ; Fernández MS; DE LA Cámara Gómez J; López MR; Vázquez MR; Folgar SC
Anticancer Res; 2013 Feb; 33(2):717-23. PubMed ID: 23393373
[TBL] [Abstract][Full Text] [Related]
18. Gefitinib in the treatment of advanced non-small-cell lung cancer.
Reck M
Expert Rev Anticancer Ther; 2009 Apr; 9(4):401-12. PubMed ID: 19374595
[TBL] [Abstract][Full Text] [Related]
19. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
Manegold C
Clin Lung Cancer; 2008; 9 Suppl 3():S100-8. PubMed ID: 19419923
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer.
Zhou S; Ren S; Yan L; Zhang L; Tang L; Zhang J; Zhou C
Respirology; 2009 Jul; 14(5):709-15. PubMed ID: 19659649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
